Document Detail


The Multicenter Isradipine/Diuretic Atherosclerosis Study: a study of the antiatherogenic properties of isradipine in hypertensive patients. MIDAS Research Group.
MedLine Citation:
PMID:  1720479     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Hypertension is a risk factor for the development of atherosclerosis and its complications, which are among the major causes of morbidity and mortality. Although recent clinical trials indicate that antihypertensive treatment reduces morbidity and mortality associated with stroke, congestive heart failure, and renal insufficiency, questions remain as to whether such treatment also prevents coronary heart disease (CHD) mortality. The observed reduction in CHD mortality from pooled clinical trial data was 10-14% and was much less than the expected 20-25% reduction for a 5-6 mm Hg reduction in diastolic pressure. One explanation may be that subtle adverse metabolic effects of treatment may have blunted the beneficial effects. Isradipine, a dihydropyridine calcium antagonist, is a potent antihypertensive drug with antiatherogenic properties in animal models. Therefore, we hypothesized that isradipine may be appropriate for testing the efficacy of antihypertensive treatment in retarding the progression of atherosclerosis in humans. The Multicenter Isradipine/Diuretic Atherosclerosis Study (MIDAS) is a clinical trial designed to compare the efficacy of isradipine (2.5 or 5 mg b.i.d.) with hydrochlorothiazide (12.5 or 25 mg b.i.d.) in retarding the progression of early carotid atherosclerosis as monitored by high-resolution B-mode ultrasonography.
Authors:
N O Borhani; M G Bond; J R Sowers; M Canossa-Terris; V Buckalew; M E Gibbons; A J Worthy
Related Documents :
19942849 - Hypertension-related cognitive decline: is the time right for intervention studies?
2653029 - Calcium antagonists in hypertension.
20619499 - Does antihypertensive drug therapy decrease morbidity or mortality in patients with a h...
19857679 - Inadequate blood pressure control in most kidney transplant recipients and patients wit...
10890479 - Perioperative blood pressure control: a prospective survey of patient management in car...
6240449 - Early versus late onset of therapy. experiences from animal studies.
23235349 - Comparative efficacy of irbesartan/ hydrochlorothiazide and valsartan/hydrochlorothiazi...
24756779 - Compliance properties of collagen-coated polyethylene terephthalate vascular prostheses.
20644419 - Acute lung injury is an independent risk factor for brain hypoxia after severe traumati...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  18 Suppl 3     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1991  
Date Detail:
Created Date:  1992-01-09     Completed Date:  1992-01-09     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S15-9     Citation Subset:  IM    
Affiliation:
University of California, Davis.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Arteriosclerosis / complications,  drug therapy*,  ultrasonography
Calcium Channel Blockers / therapeutic use*
Carotid Arteries / ultrasonography
Dihydropyridines / therapeutic use*
Double-Blind Method
Female
Humans
Hydrochlorothiazide / therapeutic use
Hypertension / complications,  drug therapy*
Isradipine
Male
Middle Aged
Chemical
Reg. No./Substance:
0/Calcium Channel Blockers; 0/Dihydropyridines; 58-93-5/Hydrochlorothiazide; 75695-93-1/Isradipine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Evaluation of isradipine and captopril alone or in combination for the treatment of hypertension.
Next Document:  Coronary vascular changes in the progression and regression of hypertensive heart disease.